Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

Deeconomics Mar. 21 at 6:35 PM

$ACHV Cigarettes are back! Hollywood is pushing a new generation to light up from coast to coast 3/20/26. https://share.google/CKcBz636WPMxGoJkM

0 · Reply

Deeconomics Mar. 20 at 11:24 AM

$ACHV PDUFA date June 20, 2026 for expected first new FDA approved smoking cessation drug in 20 years ✔️ FDA Commissioner's National Priority Voucher for vaping ✔️ Dilution for product launch ? Patent power clarity ? Conference call next week ✔️

4 · Reply

DragonAlgo Mar. 20 at 8:39 AM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-09-18 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $1.00 Stop: $0.72 TP1: $1.30 TP2: $1.70 TP3: $2.40 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

Deeconomics Mar. 19 at 5:16 PM

$ACHV Achieve Life Sciences (ACHV) cytisinicline smoking (# 1 cause of preventable death in the world) smoking cessation drug FDA PDUFA date is June 20, 2026. Recently on September 5, 2025, the World Health Organization (WHO) announced the inclusion of cytisine in its Model List of Essential Medicines. Owing to its efficacy, tolerability profile, and low cost, cytisine represents a valuable addition to the smoking cessation toolkit. The recognition of cytisine is both a triumph for global health equity and an indictment of the political, economic, and scientific inertia that kept this life-saving treatment in the shadows for more than 50 years. https://share.google/RZgOUSlheCF5Ar8Pn

0 · Reply

Deeconomics Mar. 18 at 10:47 AM

$ACHV Last month, the FDA approved Boehringer Ingelheim's drug hernexeos (NSCLC treatment) 44 days after its January 13, 2026 BLA submission. They had an accelerated FDA Commissioner's National Priority Voucher. Achieve Life Sciences cytisinicline (nicotine vaping addiction) was amongst the first nine to ever receive the voucher. That's gravy on top of the smoking PDUFA date that's only 3 months away. Unimaginable that there wouldn't be any licensing or M & A interest near term. Strategic clarity needs to be prioritized at next week's conference call.

5 · Reply

DragonAlgo Mar. 17 at 10:19 PM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-12-18 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $1.45 Stop: $1.04 TP1: $1.89 TP2: $2.47 TP3: $3.48 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

Ralphbeach Mar. 17 at 7:19 PM

$ACHV You like disruptive technology because you own $ACHV. here is another one, $BLOZF. Years ago this company got a story written in Time magazine, the stock took off. Well they have been getting it together. They make a breathalyzer for marijuana. More people are driving stoned then drunk. Check it out.

1 · Reply

HyperBulls Mar. 17 at 12:57 PM

$ACHV Achieve Life Sciences will report fourth quarter and full year 2025 financial results and provide a corporate update on March 24, 2026. The conference call and webcast are scheduled for 8:30 AM EDT. **** This is the part I’ll be waiting for: the corporate update.

2 · Reply

DragonAlgo Mar. 17 at 3:27 AM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-06-18 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.70 Stop: $0.50 TP1: $0.91 TP2: $1.19 TP3: $1.68 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

bobtheknob Mar. 16 at 11:47 PM

$ACHV https://www.zerohedge.com/markets/sec-preparing-proposal-eliminate-quarterly-reporting-requirement

1 · Reply

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

Mar 4, 2026, 8:00 AM EST - 17 days ago

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

Feb 4, 2026, 8:57 PM EST - 6 weeks ago

Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch

Feb 4, 2026, 2:43 AM EST - 6 weeks ago

Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy

Jan 30, 2026, 4:05 PM EST - 7 weeks ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Jan 12, 2026, 8:47 AM EST - 2 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Dec 17, 2025, 4:11 PM EST - 3 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Nov 6, 2025, 3:26 PM EST - 4 months ago

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 4 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 4 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 5 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 5 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 20, 2025, 7:15 AM EDT - 5 months ago

Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

Oct 17, 2025, 7:30 AM EDT - 5 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 6 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 6 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 3, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 21, 2025, 2:11 PM EDT - 7 months ago

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Aug 8, 2025, 10:12 AM EDT - 8 months ago

Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 8 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 7, 2025, 1:55 PM EDT - 9 months ago

Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation

Jun 30, 2025, 7:52 PM EDT - 9 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 9 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 9 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 9 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 3, 2025, 6:28 PM EDT - 10 months ago

Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk

May 28, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 12:16 PM EDT - 11 months ago

Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 11 months ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 11 months ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025, 2:52 PM EDT - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 9, 2024, 7:32 AM EST - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Deeconomics Mar. 21 at 6:35 PM

$ACHV Cigarettes are back! Hollywood is pushing a new generation to light up from coast to coast 3/20/26. https://share.google/CKcBz636WPMxGoJkM

0 · Reply

Deeconomics Mar. 20 at 11:24 AM

4 · Reply

DragonAlgo Mar. 20 at 8:39 AM

0 · Reply

Deeconomics Mar. 19 at 5:16 PM

0 · Reply

Deeconomics Mar. 18 at 10:47 AM

5 · Reply

DragonAlgo Mar. 17 at 10:19 PM

0 · Reply

Ralphbeach Mar. 17 at 7:19 PM

1 · Reply

HyperBulls Mar. 17 at 12:57 PM

2 · Reply

DragonAlgo Mar. 17 at 3:27 AM

0 · Reply

bobtheknob Mar. 16 at 11:47 PM

$ACHV https://www.zerohedge.com/markets/sec-preparing-proposal-eliminate-quarterly-reporting-requirement

1 · Reply

bobiartzona Mar. 16 at 1:12 PM

$ACHV Does anyone have any idea when the report will be out?

3 · Reply

DragonAlgo Mar. 16 at 12:49 PM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-03-20 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.09 Stop: $0.06 TP1: $0.12 TP2: $0.15 TP3: $0.22 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

Twills08 Mar. 15 at 7:00 PM

$ACHV Keep this on your watch list. It isn’t time to load yet, but it will be a very big mover in 1-2 months. I’m only going to mention this one sporadically. This is that mention. 👀

1 · Reply

JackFlaps Mar. 13 at 2:53 PM

$ACHV no word on quarterly meeting date or state of the very near need for dilution/financing. Did they take the month off? How far am I out of the loop here?

2 · Reply

DragonAlgo Mar. 13 at 8:37 AM

🐉 $ACHV PUT — DragonAlgo® Signal Contract: ACHV PUT Expiry: 2026-03-20 | Strike: $5.00 | Type: PUT Option Plan (premium): Entry: $0.89 Stop: $0.64 TP1: $1.16 TP2: $1.51 TP3: $2.14 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Ramanda87 Mar. 12 at 3:53 PM

$ACHV when is this going to finally take off?

1 · Reply

bobiartzona Mar. 12 at 1:15 PM

$ACHV $ACHV – The Big Pharma Trap 🧬 "Big Pharma doesn't want this drug on the market. They want to keep you trapped in a cycle of nicotine patches and gums. Why? Because those products don't cure the addiction—they just keep you paying for it. They want to push their synthetics and nicotine-loaded trash while you stay hooked. But $ACHV is a threat to their business model. A plant-based solution that actually works in 6 to 12 weeks is their worst nightmare. They want customers, not cures. The era of their nicotine-trap is over.

2 · Reply

bobiartzona Mar. 12 at 12:58 PM

$ACHV $ACHV – You are missing the big picture. 🖼️ The moment this hits the market, everything else becomes obsolete. Nicotine patches, gums, and synthetic drugs with questionable ingredients and scary side effects are done. There is a massive vacuum in the smoking cessation market, and there will be only one King. We are looking at a total shift in how people quit smoking. If you see the industrial foundation behind this, you know the outcome. 👑🚀

0 · Reply

RickyIsRich Mar. 12 at 12:54 PM

$ACHV this is not a good drug i wouldn’t touch with a 20 foot pole

2 · Reply

bobiartzona Mar. 12 at 12:30 PM

$ACHV 🛡️ THE FINAL PROOF (Direct from Sopharma) The Quote: "We have successfully completed the large-scale modernization of our extraction capacities in Kazanlak. This facility is now ready to support our global expansion strategy, specifically ensuring the high-volume production of active substances required for international partnerships in regulated markets like the US." What this means in plain English: "Regulated markets like the US" – This is code for FDA approval. You don't build a plant for the US market if you aren't 100% sure about the quality of your molecule. "Global expansion" – Sopharma isn't thinking about Bulgaria anymore. They are thinking about the $13 Billion US smoking cessation market. The "Big Fish" Move: Sopharma’s management just acquired millions in warrants. They aren't just the manufacturers; they are the biggest "insiders" in the game.

0 · Reply

bobiartzona Mar. 12 at 12:13 PM

$ACHV $ACHV - The Supply Chain is Ready 🚀 "Stop worrying about 'supply' issues. Sopharma (the manufacturer) has already secured the backbone: Kazanlak Plant: A high-tech facility dedicated to Cytisine extraction. Capacity: 2,000 tons of raw material processing = 70 tons of pure API per year. Ready for US: This facility is built to cGMP standards, specifically to supply Achieve through 2037. While people are waiting for an earnings date, the manufacturer has already invested millions into industrial-scale production. They aren't building a 70-ton capacity plant for a 'maybe.' They are ready for a mass-market launch. $ACHV"

0 · Reply

bobiartzona Mar. 12 at 12:03 PM

$ACHV $ACHV - The 60-Year Evidence Established: Launched in 1964 (60+ years of real-world use). Scale: Over 20 million people treated in Europe and Russia (per official SEC filings). Science: Clinical trials (ORCA-2/3) show a 6x higher quit rate vs. placebo. Safety: 6 decades of history with an impeccable safety profile.

0 · Reply

Market Cap	215.07M
Revenue (ttm)	0.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.04

Volume	309,800
Avg Vol	550,134
Day's Range	N/A - N/A
Shares Out	53.23M
Stochastic %K	8%
Beta	1.81
Analysts	Strong Sell
Price Target	$15.57